... / ... / ... / Research groups / Hereditary Cancer

Hereditary Cancer

In 1992 the Rotterdam Family Cancer Clinic was established in a collaborative effort of clinicians from the various departments involved in the care of breast and ovarian cancer, to provide counseling, surveillance, prevention and treatment of both affected and healthy members of families with clustering of breast and/or ovarian cancer. The collaboration led to the formation of a multidisciplinary working group “Hereditary Cancer”. Clinicians, researchers and psychosocial workers are involved, addressing all aspects of hereditary breast and ovarian cancer. So far, genetic, epidemiologic and oncologic data of more than 4500 families with hereditary breast and/or ovarian cancer have been registered at the Family Cancer Clinic.
The collaborative effort of the working group “Hereditary Cancer” has been contributing to a better insight into the efficacy and side effects of primary and secondary preventive measures, the characteristics and clinical course of hereditary breast and ovarian cancer, the preferences and decisions of women regarding genetic testing and the psychosocial burden associated with it.

Our research focuses on optimization of the counselling and treatment of patients with hereditary breast and/or ovarian cancer, with specific interest into:
 
1. Sensitivity to chemotherapy in BRCA1/2-associated breast and ovarian cancer
2. Prophylactic measures and early diagnostics
3. Risk prediction and prognosis of contralateral breast cancer
4. Identification of genes associated with breast and ovarian cancer: in collaboration

WET1

Publications

Two key publications
Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, Ausems MG, Collée JM, van Doorn HC, Gomez Garcia EB, Kets CM, van Leeuwen FE, Meijers-Heijboer HE, Mourits MJ, van Os TA, Vasen HF, Verhoef S, Rookus MA*, Hooning MJ*; Hereditary Breast and Ovarian Cancer Research Group Netherlands. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. 2015 Mar 18;107(5).

Kriege M, Brekelmans CTM, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MMA, Muller SH, Meijer S, Oosterwijk JC, Beex LVAM, Tollenaar RAEM, de Koning HJ, Rutgers EJT, Klijn JGM. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N.Engl.J Med. 2004;351(5):427-437. PubMed

Two recent publications
van den Broek AJ, van 't Veer LJ, Hooning MJ, Cornelissen S, Broeks A, Rutgers EJ, Smit VT, Cornelisse CJ, van Beek M, Janssen-Heijnen ML, Seynaeve C, Westenend PJ, Jobsen JJ, Siesling S, Tollenaar RA, van Leeuwen FE, Schmidt MK. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers. J Clin Oncol. 2016 Feb 10;34(5):409-18.

Drooger JC, Hooning MJ, Seynaeve C, Baaijens M, Obdeijn AIM, Sleijfer S, Jager A. Diagnostic and therapeutic ionizing radiation and the risk of first and secondary primary breast cancer, with special attention for BRCA1 and BRCA2 germline mutation carriers. Cancer Treat Rev. 2015 Feb;41(2):187-96.